KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EPS (Weighted Average and Diluted): 2011-2024

Historic EPS (Weighted Average and Diluted) for Sarepta Therapeutics (SRPT) over the last 6 years, with Dec 2024 value amounting to $2.34.

  • Sarepta Therapeutics' EPS (Weighted Average and Diluted) fell 1305.41% to -$4.46 in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.19, marking a year-over-year increase of 57.64%. This contributed to the annual value of $2.34 for FY2024, which is 140.34% up from last year.
  • According to the latest figures from FY2024, Sarepta Therapeutics' EPS (Weighted Average and Diluted) is $2.34, which was up 140.34% from -$5.80 recorded in FY2023.
  • Sarepta Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $2.34 during FY2024, with a 5-year trough of -$8.03 in FY2022.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$5.80 (2023), whereas its average is -$3.83.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 55.92% in 2022, then skyrocketed by 140.34% in 2024.
  • Sarepta Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$7.11 in 2020, then grew by 27.57% to -$5.15 in 2021, then slumped by 55.92% to -$8.03 in 2022, then grew by 27.77% to -$5.80 in 2023, then surged by 140.34% to $2.34 in 2024.